Does including informal care in economic evaluations matter? A systematic review of inclusion and impact of informal care in cost-effectiveness studies
- PMID: 25315368
- DOI: 10.1007/s40273-014-0218-y
Does including informal care in economic evaluations matter? A systematic review of inclusion and impact of informal care in cost-effectiveness studies
Abstract
Background: Informal care makes an important contribution to societal welfare. However, it may involve substantial time costs and can have a considerable negative effect on the health and well-being of informal caregivers. These costs and effects of informal caregiving are often excluded in economic evaluations of healthcare interventions. The impact of this exclusion on the outcomes of these evaluations is largely unknown.
Objectives: This study aimed to explore the inclusion of informal care in economic evaluations and the potential impact of the costs and effects of informal caregiving on cost-effectiveness outcomes.
Methods: A systematic review was conducted to identify economic evaluations of interventions in four distinct disease areas where informal care is potentially important: Alzheimer's disease, metastatic colorectal cancer, Parkinson's disease and rheumatoid arthritis. It was recorded how often economic evaluations included informal caregiving. Next, for the studies including informal care, the impact on cost-effectiveness outcomes was determined by removing informal care costs and effects of the cost-effectiveness calculations and recalculating the outcomes. The new cost-effectiveness outcomes were then compared with the original reported outcomes.
Results: The study identified 100 economic evaluations investigating interventions targeted at Alzheimer's disease (n = 25), metastatic colorectal cancer (n = 24), Parkinson's disease (n = 8) and rheumatoid arthritis (n = 43). Twenty-three of these evaluations (23 %) included costs and/or effects of informal caregiving: 64 % of the Alzheimer's disease studies, 0 % of the metastatic colorectal cancer studies, 13 % of Parkinson's disease studies and 14 % of rheumatoid arthritis studies. When informal care was included, this mostly concerned time costs. Studies rarely included both costs and effects. The effect of including or excluding informal care costs or effects on cost-effectiveness outcomes in most studies was modest, but in some studies the impact was strong.
Conclusion: Most economic evaluations in the area of Alzheimer's disease include costs and/or effects related to informal caregiving. However, in other disease areas where informal caregiving is common it seems that the majority of economic evaluations ignore informal caregiving. The inclusion of informal care can have a strong impact on cost-effectiveness outcomes. Future economic evaluations should therefore consider the relevance of informal care in the context of their study, and either include these costs and effects or justify why they were excluded.
Similar articles
-
How relevant are social costs in economic evaluations? The case of Alzheimer's disease.Eur J Health Econ. 2019 Nov;20(8):1207-1236. doi: 10.1007/s10198-019-01087-6. Epub 2019 Jul 24. Eur J Health Econ. 2019. PMID: 31342208 Free PMC article.
-
Family and Caregiver Spillover Effects in Cost-Utility Analyses of Alzheimer's Disease Interventions.Pharmacoeconomics. 2019 Apr;37(4):597-608. doi: 10.1007/s40273-019-00788-3. Pharmacoeconomics. 2019. PMID: 30903567
-
The inclusion of informal care in applied economic evaluation: a review.Value Health. 2012 Sep-Oct;15(6):975-81. doi: 10.1016/j.jval.2012.05.009. Value Health. 2012. PMID: 22999150 Review.
-
Measuring and Valuing Informal Care for Economic Evaluation of HIV/AIDS Interventions: Methods and Application in Malawi.Value Health Reg Issues. 2016 Sep;10:73-78. doi: 10.1016/j.vhri.2016.08.002. Epub 2016 Sep 16. Value Health Reg Issues. 2016. PMID: 27881282 Free PMC article.
-
Quantifying Family Spillover Effects in Economic Evaluations: Measurement and Valuation of Informal Care Time.Pharmacoeconomics. 2019 Apr;37(4):461-473. doi: 10.1007/s40273-019-00782-9. Pharmacoeconomics. 2019. PMID: 30953263 Free PMC article. Review.
Cited by
-
Cost-effectiveness of early intervention in psychosis in low- and middle-income countries: economic evaluation from São Paulo, Brazil.Epidemiol Psychiatr Sci. 2024 Apr 5;33:e21. doi: 10.1017/S2045796024000222. Epidemiol Psychiatr Sci. 2024. PMID: 38576239 Free PMC article.
-
Mapping of Family Reported Outcome Measure (FROM-16) scores to EQ-5D: algorithm to calculate utility values.Qual Life Res. 2024 Apr;33(4):1107-1119. doi: 10.1007/s11136-023-03590-z. Epub 2024 Feb 25. Qual Life Res. 2024. PMID: 38402530 Free PMC article. Clinical Trial.
-
Methods used to account for caregivers' sex and gender within studies examining the financial burden of caregivers of children and adolescents : Results from a scoping review.Clinicoecon Outcomes Res. 2024 Jan 26;16:35-53. doi: 10.2147/CEOR.S443077. eCollection 2024. Clinicoecon Outcomes Res. 2024. PMID: 38298908 Free PMC article. Review.
-
The Economic Costs of Informal Care: Estimates from a National Cross-Sectional Survey in The Netherlands.Eur J Health Econ. 2024 Jan 31. doi: 10.1007/s10198-023-01666-8. Online ahead of print. Eur J Health Econ. 2024. PMID: 38294595
-
On spillovers in economic evaluations: definition, mapping review and research agenda.Eur J Health Econ. 2024 Jan 23. doi: 10.1007/s10198-023-01658-8. Online ahead of print. Eur J Health Econ. 2024. PMID: 38261132
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical